BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qing S, Ji D, Li B, Li F, Wang Y, Niu X, Ling B, Meng Y, Lau G, Chen G. Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus. Ann Saudi Med 2015;35:293-7. [PMID: 26497709 DOI: 10.5144/0256-4947.2015.293] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gitto S, Cicero AF, Loggi E, Giovannini M, Conti F, Grandini E, Guarneri V, Scuteri A, Vitale G, Cursaro C, Borghi C, Andreone P. Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. Annals of Hepatology 2018;17:64-75. [DOI: 10.5604/01.3001.0010.7536] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
2 Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 27-38. e4. [PMID: 28479504 DOI: 10.1016/j.cgh.2017.04.038] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 15.4] [Reference Citation Analysis]
3 Li J, Li L, Guo D, Li S, Zeng Y, Liu C, Fu R, Huang M, Xie W. Triglyceride metabolism and angiopoietin-like proteins in lipoprotein lipase regulation. Clin Chim Acta 2020;503:19-34. [PMID: 31923423 DOI: 10.1016/j.cca.2019.12.029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
4 Özdoğan O, Yaraş S, Ateş F, Üçbilek E, Sezgin O, Altıntaş E. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent? Turk J Gastroenterol 2020;31:384-92. [PMID: 32519958 DOI: 10.5152/tjg.2020.19273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ji D, Chen GF, Niu XX, Zhang M, Wang C, Shao Q, Wu V, Wang Y, Cheng G, Hurwitz SJ, Schinazi RF, Lau G. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090. [PMID: 33889834 DOI: 10.1016/j.metop.2021.100090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
7 Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Lu M; CHeCS Investigators. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int. 2019;39:1027-1032. [PMID: 30570808 DOI: 10.1111/liv.14031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
8 Andrade VG, Yamashiro FDS, Oliveira CV, Kurozawa LL, Moreira A, Silva GF. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION? Arq Gastroenterol 2018;55:184-7. [PMID: 30043871 DOI: 10.1590/S0004-2803.201800000-33] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Li Y, Wang X, Yu G, Sun H, Lv J, Chi X, Wu R, Gao X, Niu J. The association of hepatitis c virus infection status with serum glucose levels. BMC Gastroenterol. 2019;19:86. [PMID: 31195990 DOI: 10.1186/s12876-019-1003-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Beig J, Orr D, Harrison B, Gane E. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients. Liver Transpl 2018;24:1031-9. [PMID: 29577581 DOI: 10.1002/lt.25060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
11 Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, Krkoska D, Mazuchova E, Piesecka L, Vahalova V, Rac M, Schreter I, Virag L, Koller T, Liptakova A, Ondrasova M, Jarcuska P. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. Can J Gastroenterol Hepatol 2018;2018:6095097. [PMID: 30402450 DOI: 10.1155/2018/6095097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
12 Lacerda GS, Medeiros T, Rosário NFD, Peralta RHS, Cabral-Castro MJ, Esberard EBC, Andrade TG, Xavier AR, Silva AA. Exploring lipid and apolipoprotein levels in chronic hepatitis C patients according to their response to antiviral treatment. Clin Biochem 2018;60:17-23. [PMID: 30030979 DOI: 10.1016/j.clinbiochem.2018.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]